Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
NMC Case Report Journal|June 25, 2025
Repeated Recurrence of Spontaneous Cervical Epidural Hematoma Associated with Habitual Strength TrainingYuki Watabe, Kyoka Nishita, Kaoru Tomikawa, et al.Neurologia Medico-Chirurgica|October 29, 2013
Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institutionHiroshi Aoki, Ryosuke Ogura, Yoshihiro Tsukamoto, et al.No Shinkei Geka. Neurological Surgery|June 7, 2021
[The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors]Manabu Natsumeda, Jotaro On, Jun Watanabe, et al.Journal of Neuro-Oncology|April 10, 2024
Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapyNatsuko Kondo, Tadatoshi Kinouchi, Manabu Natsumeda, et al.World Neurosurgery|May 18, 2019
Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative PeriodJun Watanabe, Manabu Natsumeda, Masayasu Okada, et al.Neurochemical Research|March 29, 2022
JNK1-Dependent Phosphorylation of GAP-43 Serine 142 is a Novel Molecular Marker for Axonal GrowthMasayasu Okada, Yosuke Kawagoe, Toshiyuki Takasugi, et al.Journal of Pediatric Endocrinology & Metabolism : JPEM|July 3, 2024
Robust growth hormone responses to GH-releasing peptide 2 in adolescentsTakanori Onuki, Tadokoro Hiroaki, Kentaro Sawano, et al.Neurologia Medico-Chirurgica|June 1, 2018
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant GliomasHideaki Abe, Manabu Natsumeda, Yu Kanemaru, et al.Journal of Orthopaedic Surgery and Research|March 6, 2020
The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3Tomotake Kanai, Naoki Kondo, Masayasu Okada, et al.JCO Precision Oncology|February 1, 2022
High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS LymphomasJun Watanabe, Manabu Natsumeda, Masayasu Okada, et al.Pageof 6